TY  - JOUR
AU  - Walter, Christina B
AU  - Hartkopf, Andreas D
AU  - Hein, Alexander
AU  - Fasching, Peter A
AU  - Kolberg, Hans-Christian
AU  - Hadji, Peyman
AU  - Tesch, Hans
AU  - Häberle, Lothar
AU  - Ettl, Johannes
AU  - Lüftner, Diana
AU  - Wallwiener, Markus
AU  - Müller, Volkmar
AU  - Beckmann, Matthias W
AU  - Michel, Laura L
AU  - Belleville, Erik
AU  - Huebner, Hanna
AU  - Uhrig, Sabrina
AU  - Goossens, Chloë
AU  - Wimberger, Pauline
AU  - Hielscher, Carsten
AU  - Meyer, Julia
AU  - Mundhenke, Christoph
AU  - Kurbacher, Christian
AU  - Wuerstlein, Rachel
AU  - Untch, Michael
AU  - Janni, Wolfgang
AU  - Taran, Florin-Andrei
AU  - Lux, Michael P
AU  - Wallwiener, Diethelm
AU  - Brucker, Sara Y
AU  - Schneeweiss, Andreas
AU  - Fehm, Tanja N
AU  - Fremd, Carlo
TI  - Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer.
JO  - The breast
VL  - 80
SN  - 0960-9776
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-00361
SP  - 104412
PY  - 2025
AB  - Patients with first-line metastatic breast cancer (MBC) comprise patients with de novo metastases (dnMBC) or recurrent disease after primary breast cancer (rMBC). This analysis aimed to explore the prognostic value of dnMBC versus rMBC overall and particularly in subgroups according to age and metastasis site, in addition to other prognostic clinicopathological parameters in a first-line, hormone receptor (HR)-positive, HER2-negative (HRpos/HER2neg) population.Within the prospective PRAEGNANT MBC registry (NCT02338167), 508 HRpos/HER2neg patients, receiving first-line treatment for advanced disease, were identified. Clinicopathological parameters (age, body mass index, performance status, tumor grading, metastasis site and therapy) were assessed according to metastatic status (dnMBC, rMBC within 5 years of primary diagnosis (rMBC <5 years), rMBC after more than 5 years (rMBC ≥5 years)). Cox regression analyses were performed to investigate whether metastatic status influences progression-free survival (PFS) and overall survival (OS).De novo metastatic disease was present in 180 patients (35.4 
KW  - Advanced breast cancer (Other)
KW  - First line therapy (Other)
KW  - HER2-negative (Other)
KW  - Hormone receptor-positive (Other)
KW  - Metastasis (Other)
KW  - de novo metastatic breast cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39952220
DO  - DOI:10.1016/j.breast.2025.104412
UR  - https://inrepo02.dkfz.de/record/298927
ER  -